Vancomycin minimum inhibitory concentration, host comorbidities and mortality in staphylococcus aureus bacteraemia

24Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We reported an association between elevated vancomycin MIC and 30-day mortality in patients with Staphylococcus aureus bacteraemia (SAB), including patients with methicillin-susceptible S. aureus (MSSA) treated with flucloxacillin. A detailed analysis of comorbidities and disease severity scores in the same cohort of patients was performed to ascertain if unknown clinical parameters may have influenced these results. The association between elevated vancomycin MIC and 30-day mortality in SAB remained significant (p 0.001) on multivariable logistic regression analysis even when accounting for clinical factors. In addition, the association persisted when restricting analysis to patients with MSSA bacteraemia treated with flucloxacillin. This suggests that elevated vancomycin MIC is associated with but not causally linked to an organism factor that is responsible for increased mortality. © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Cite

CITATION STYLE

APA

Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O’Sullivan, M. V. N., … Howden, B. P. (2013). Vancomycin minimum inhibitory concentration, host comorbidities and mortality in staphylococcus aureus bacteraemia. Clinical Microbiology and Infection, 19(12), 1163–1168. https://doi.org/10.1111/1469-0691.12168

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free